

FW: FOI 24/021 - RE: Request under Freedom of Information Act

Pharmacovigilanceser <vigilanceservice@mhra.gov.uk>

Tue 23/01/2024 14:46

[REDACTED] MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>

📎 1 attachments (1 MB)

RMP_PLGB 08829-0204_Redacted.pdf;

Hi Both,

For your records.

Many thanks,

[REDACTED]

From: Pharmacovigilanceser

Sent: Tuesday, January 23, 2024 2:45 PM

To: [REDACTED]

Subject: FOI 24/021 - RE: Request under Freedom of Information Act

Dear [REDACTED]

FOI 24/021

Thank you for your email, dated 05/01/2024, in which you requested:

“a copy of the Risk Management Plan for PLGB 08829/0204.”

We can confirm that the MHRA holds a copy of the requested RMP.

Information that has been redacted is exempt under Section 40 (Personal Information) or Section 43 (Commercial Interests) of the Freedom of Information (FOI) Act and is therefore withheld.

Section 40 provides that personal information may be exempt from release where to do so would contravene data protection principles. Section 43 provides that information will be exempt from release where to do so would or would be likely to prejudice commercial interests. Furthermore, we do not believe that there is an overriding public interest in disclosing the redacted information in this instance.

We hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Please remember to quote the reference number above in any future communications.

Yours sincerely,

FOI Team

Safety & Surveillance Group

Medicines and Healthcare Products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU

[Medicines and Healthcare products Regulatory Agency - GOV.UK \(www.gov.uk\)](https://www.gov.uk)
[Yellow Card | Making medicines and medical devices safer \(mhra.gov.uk\)](https://www.gov.uk/guidance/yellow-card)
Follow us on social media [Medicines and Healthcare products Regulatory Agency - GOV.UK \(www.gov.uk\)](https://www.gov.uk)

From: [REDACTED]
Sent: Friday, January 5, 2024 4:49 PM
To: MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>
Subject: FOI 24/021 - Request under Freedom of Information Act

You don't often get email from [REDACTED]

Dear Sir/Madam,

Under the Freedom of Information Act, I would kindly wish to request the currently approved Risk Management Plan for drug product Raxone 150mg film-coated tablets (PLGB 08829/0204).

Thank you.

Kind regards,

[REDACTED]

[REDACTED]

The information transmitted may contain confidential material and is intended only for the person or entity to which it is addressed. Any review, retransmission, dissemination or other use of, or taking of any action by persons or entities other than the intended recipient is prohibited. If you are not the intended recipient, please delete the information from your system and contact the sender.

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)